Anhydramnios following trastuzumab and paclitaxel for metastatic breast cancer in pregnancy

Purpose: Metastatic breast cancer in pregnancy is a rare condition. Decision about therapy should be made after weighing fetal risks versus the expected benefit. Trastuzumab is known to cause fetal renal insufficiency and anhydramnios, but some women clearly benefit from treatment. Material and methods: We report on a 32-year-old pregnant woman with trastuzumab/paclitaxel therapy for recurrent metastatic breast cancer. Results: Primary diagnosis of invasive-ductal breast cancer was in the first pregnancy. The tumor was ER/PR negative, without HER-2 overexpression, T2N1aM0. Mastectomy and axillary lymphadenectomy…